Murugesh Kandasamy is a senior research scientist at the Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh. He holds a bachelor’s and master’s degree in pharmacy from The Tamil Nadu Dr. M.G.R. Medical University, India, and earned his Ph.D. in Pharmaceutical Sciences from Jadavpur University, India. After completing his doctoral studies, Dr. Murugesh gained industry experience as a Research Scientist in various contract research organizations (CROs) in India, where he was actively involved in developing and validating bioanalytical methods for new drug entities. He then pursued advanced postdoctoral training at two prestigious institutions in the United States: Ivy Brain Tumor Center in Phoenix, Arizona, and the Indiana Clinical and Translational Sciences Institute (CTSI) in Indianapolis, Indiana. As a Senior Research Scientist in drug discovery, Dr. Murugesh has served as a key DMPK representative across various stages of preclinical and clinical development. His research interests are rooted in pharmacokinetics and pharmacodynamics (PK/PD), with a particular focus on physiologically based pharmacokinetic (PBPK) modeling. He has considerable experience utilizing modeling and simulation software such as GastroPlus, Phoenix WinNonlin, Simcyp, Monolix®, and R/RStudio. Dr. Murugesh’s work contributes to informed decision-making in lead candidate selection and dosage optimization, advancing the development of safer and more effective therapeutic agents.
Centers
- Center for Education and Drug Abuse Research
- Pittsburgh Pharmacogenomics (PittPGx)
- Center for Clinical Pharmaceutical Sciences
- PhD
Education & Training
- Drug Discovery and Development
- Clinical Pharmaceutical Sciences
- Systems Pharmacology and Outcomes
- Drug Abuse and Prevention
- Pharmacogenetics
- Jesudaso et al, Murugesh Kandasamy. SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer’s disease, Alzheimer's & Dementia, Translational & clinical interventions, Nov 2023; Vol 9(4), e12429.
- Sara K. Quinney, Kandasamy M, Adrian Oblak, Kristen D. Onos, Mike Sasner, Anna K. Greenwood, Kara H. Woo, Stacey J. Sukoff Rizzo, Paul R. Territo. STOP‐AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer’s disease, Alzheimer's & Dementia, May 2023, PMID: 37157089.
- Kohli S, Bhatia S, Banavar SR, Al-Haddad A, Kandasamy M, Qasim SSB, Kit-Kay M, Pichika MR, Daood U. In-vitro evaluation of the effectiveness of polyphenols based strawberry extracts for dental bleaching. Sci Rep. 2023;13(1):4181, PMID: 36914760.
- Quinney SK, Bies RR, Grannis SJ, Bartlett CW, Mendonca E, Rogerson CM, Backes CH, Shah DK, Tillman EM, Costantine MM, Aruldhas BW, Allam R, Grant A, Abbasi MY, Kandasamy M, Zang Y, Wang L, Shendre A, Li L. The MPRINT Hub Data, Model, Knowledge and Research Coordination Center: Bridging the gap in maternal-pediatric therapeutics research through data integration and pharmacometrics. Pharmacotherapy. 2023, PMID: 36625779.
- Madheswaran T, Kandasamy M, Bose RJ, Karuppagounder V. Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems. Drug Discov Today. 2019;24(7):1405-1412, PMID: 36625779.
